| 76 | 0 | 235 |
| 下载次数 | 被引频次 | 阅读次数 |
目的 系统梳理全球尼帕病毒研究的发文趋势、合作网络、知识基础及主题演化，重点辨析相较截至2018年、2020年和2023年的既往文献计量研究所新增的认识。方法 以Web of Science Core Collection的Science Citation Index Expanded为数据源，于2026年6月11日采用主题检索式TS=("Nipah virus*"OR"Nipah henipavirus"OR"Henipavirus nipahense"OR"Nipah encephalitis")检索所有年份文献。合并、去重并排除2026年不完整年度数据、非Article/Review文献、核心主题字段未明确涉及Nipah的记录、撤稿文献和重复收录记录后，纳入1999-2025年文献1495篇。采用VOSviewer 1.6.21和自编程序进行年度发文统计、合作网络、关键词共现与平均发表年份叠加及被引参考文献共被引分析。结果 1999-2008年、2009-2018年和2019-2025年分别发表235篇（15.7%）、494篇（33.0%）和766篇（51.2%）,2025年发文量最高（169篇）。美国发文量居首（661篇）；孟加拉国国际腹泻病研究中心发文79篇，但总联系强度为253，接近美国疾病预防控制中心的262，显示流行地区现场证据节点具有较强的国际连接。关键词平均发表年份仅用于定位候选前沿；结合2024-2025年代表性进展，多种疫苗平台进入Ⅰ期人体评价，抗病毒研究推进至聚合酶结构与筛选体系及动物模型中的生物治疗验证，One Health与溢出风险研究开始整合人、动物宿主、环境和行为暴露证据。共被引网络包含89篇参考文献和3个聚类，Chua等2000年发表于Science的论文在本数据集中被引604次，居首位。结论 相较既往文献计量研究，本研究新增认识不在高产主体排名，而在于识别2024-2025年临床转化和跨界风险研究的实质性进展，并揭示流行地区现场贡献与高水平实验和转化资源集中地区之间的结构性错配。未来应加强流行地区主导的持续监测、平等的数据和样本治理及早期转化研究。
Abstract：Objective To characterize global Nipah virus research and identify substantive advances beyond bibliometric studies ending in 2018, 2020, or 2023. Methods The Science Citation Index Expanded of the Web of Science Core Collection was searched on June 11, 2026 using TS=( "Nipah virus*" OR "Nipah henipavirus" OR "Henipavirus nipahense" OR "Nipah encephalitis") for all years. After merging, deduplication, and exclusion of incomplete 2026 records, non-article/review document types, records without an explicit Nipah focus in core topic fields, one retracted publication, and one duplicate record, 1,495 publications from 1999 to 2025 were included. VOSviewer 1.6.21 and custom scripts were used for annual publication statistics, collaboration analyses, keyword co-occurrence and overlay analyses, and cited-reference co-citation analysis. Results A total of 235(15.7%), 494(33.0%), and 766(51.2%) publications appeared in 1999-2008, 2009-2018, and 2019-2025, respectively; annual output peaked at 169 in 2025. The USA led in publications(n=661). Although icddr,b produced 79 publications, its total link strength(253) approached that of the US Centers for Disease Control and Prevention(262), highlighting the strong international connectivity of a fieldevidence node in an outbreak-prone setting. Average keyword publication year was used only to identify candidate fronts. Representative 2024-2025 evidence showed that multiple vaccine platforms entered phase 1 human evaluation; antiviral work advanced through polymerase structures, screening assays, and a biologic therapeutic in animal models; and One Health/spillover research increasingly integrated human, animal-host, environmental, and behavioral evidence. The co-citation network contained 89 references and three clusters; the 2000 Science article by Chua et al. ranked first with 604 citations within the dataset. Conclusion Beyond extending the time window, this study identifies a 2024-2025 translational shift toward human vaccine evaluation, antiviral discovery platforms, and operational spillover-risk assessment, while revealing a structural mismatch between outbreak-prone settings and the concentration of advanced experimental and translational resources. Endemic-setting leadership, equitable data and specimen governance, sustained surveillance, and early translational research should be strengthened.
[1]World Health Organization. Nipah virus[EB/OL].(2026-01-29)[2026-08-12]. https：//www. who. int/news-room/fact-sheets/detail/nipah-virus.
[2]郑文江，杨秋雨，田加盛，等.尼帕病毒病原学、流行病学、诊断技术、防控策略与疫苗的研究进展[J].病毒学报，2026,42(4):1112-1127. DOI:10. 13242/j. cnki.bingduxuebao. 260065.
[3]Ang BSP, Lim TCC, Wang L. Nipah virus infection[J]. J Clin Microbiol, 2018, 56(6):e01875-17. DOI:10. 1128/JCM. 01875-17.
[4]Yob JM, Field H, Rashdi AM, et al. Nipah virus infection in bats(order Chiroptera)in peninsular Malaysia[J]. Emerg Infect Dis, 2001, 7(3):439-441.DOI:10. 3201/eid0703. 010312.
[5]Luby SP, Rahman M, Hossain MJ, et al. Foodborne transmission of Nipah virus, Bangladesh[J]. Emerg Infect Dis, 2006, 12(12):1888-1894. DOI:10. 3201/eid1212. 060732.
[6]Gurley ES, Montgomery JM, Hossain MJ, et al.Person-to-person transmission of Nipah virus in a Bangladeshi community[J]. Emerg Infect Dis, 2007, 13(7):1031-1037. DOI:10. 3201/eid1307. 061128.
[7]McKee CD, Islam A, Luby SP, et al. The ecology of Nipah virus in Bangladesh:a nexus of land-use change and opportunistic feeding behavior in bats[J]. Viruses,2021, 13(2):169. DOI:10. 3390/v13020169.
[8]Safahieh H, Sanni SA, Zainab AN. International contribution to Nipah virus research 1999-2010[J].Malays J Libr Inf Sci, 2012, 17(3):35-47.
[9]Gupta BM, Ahmed KKM, Gupta R. Nipah virus research:a scientometric assessment of global publications output during 1999-2018[J]. Int J Med Public Health, 2018, 8(2):48-55. DOI:10. 5530/ijmedph. 2018. 2. 11.
[10]Sivaprakasam S, Joshua V. Nipah virus:an exploratory scientometrics analysis, 1999-2018[J]. J Scientometr Res, 2019, 8(2):109-116. DOI:10. 5530/jscires. 8. 2. 17.
[11]Singh N, Brar RS, Chavan SB, et al. Scientometric analyses and visualization of scientific outcome on Nipah virus[J]. Curr Sci, 2019, 117(10):1574-1584. DOI:10. 18520/cs/v117/i10/1574-1584.
[12]Stable-Rodríguez Y, Machado Rivero MO, DíazChieng LY. Nipah virus:analysis of the scientific production in open access on the Web of Science, 2000-2020[J]. Salud Cienc Tecnol, 2023, 3:325. DOI:10. 56294/saludcyt2023325.
[13]Klingelhöfer D, Braun M, Naser CA, et al. Emerging Nipah virus with pandemic potential and high mortality rates:is the scientific community learning from former pandemics?[J]. Rev Med Virol, 2025, 35(2):e70028. DOI:10. 1002/rmv. 70028.
[14]Donthu N, Kumar S, Mukherjee D, et al. How to conduct a bibliometric analysis:an overview and guidelines[J]. J Bus Res, 2021, 133:285-296. DOI:10. 1016/j. jbusres. 2021. 04. 070.
[15]van Eck NJ, Waltman L. Software survey:VOSviewer, a computer program for bibliometric mapping[J]. Scientometrics, 2010, 84(2):523-538.DOI:10. 1007/s11192-009-0146-3.
[16]Negrete OA, Levroney EL, Aguilar HC, et al.EphrinB2 is the entry receptor for Nipah virus, an emergent deadly paramyxovirus[J]. Nature, 2005, 436(7049):401-405. DOI:10. 1038/nature03838.
[17]Bonaparte MI, Dimitrov AS, Bossart KN, et al.Ephrin-B2 ligand is a functional receptor for Hendra virus and Nipah virus[J]. Proc Natl Acad Sci U S A,2005, 102(30):10652-10657. DOI:10. 1073/pnas. 0504887102.
[18]Chadha MS, Comer JA, Lowe L, et al. Nipah virusassociated encephalitis outbreak, Siliguri, India[J].Emerg Infect Dis, 2006, 12(2):235-240. DOI:10. 3201/eid1202. 051247.
[19]Hsu VP, Hossain MJ, Parashar UD, et al. Nipah virus encephalitis reemergence, Bangladesh[J]. Emerg Infect Dis, 2004, 10(12):2082-2087. DOI:10. 3201/eid1012. 040701.
[20]Luby SP, Hossain MJ, Gurley ES, et al. Recurrent zoonotic transmission of Nipah virus into humans,Bangladesh, 2001-2007[J]. Emerg Infect Dis, 2009, 15(8):1229-1235. DOI:10. 3201/eid1508. 081237.
[21]Bossart KN, Zhu Z, Middleton D, et al. A neutralizing human monoclonal antibody protects against lethal disease in a new ferret model of acute Nipah virus infection[J]. PLoS Pathog, 2009, 5(10):e1000642.DOI:10. 1371/journal. ppat. 1000642.
[22]Lo MK, Spengler JR, Welch SR, et al. Evaluation of a single-dose nucleoside-modified messenger RNA vaccine encoding Hendra virus-soluble glycoprotein against lethal Nipah virus challenge in Syrian hamsters[J]. J Infect Dis, 2020, 221(Suppl 4):S493-S498. DOI:10. 1093/infdis/jiz553.
[23]de Wit E, Williamson BN, Feldmann F, et al. Late remdesivir treatment initiation partially protects African green monkeys from lethal Nipah virus infection[J].Antiviral Res, 2023, 216:105658. DOI:10. 1016/j.antiviral. 2023. 105658.
[24]Frenck RW, Naficy A, Feser J, et al. Safety and immunogenicity of a Nipah virus vaccine(HeV-sG-V)in adults:a single-centre, randomised, observer-blind,placebo-controlled, phase 1 study[J]. Lancet, 2025,406(10521):2792-2803. DOI:10. 1016/S0140-6736(25)01390-X.
[25]Gómez Román R, Wang LF, Lee B, et al. Nipah@20:lessons learned from another virus with pandemic potential[J]. mSphere, 2020, 5(4):e00602-20. DOI:10. 1128/mSphere. 00602-20.
[26]魏岚，张良一，胡大伟，等.《病毒学报》2020—2024年学术影响力分析[J].病毒学报，2024,40(6):1323-1327.DOI:10. 13242/j. cnki. bingduxuebao. 004620.
[27]ISRCTN Registry. A study of a new vaccine against Nipah virus in adults aged 18 to 55 years(ISRCTN87634044)[EB/OL].[2026-08-26].https：//doi. org/10. 1186/ISRCTN87634044.
[28]ClinicalTrials. gov. escalationDose, open-label clinical trial to evaluate safety, tolerability and immunogenicity of a Nipah virus mRNA vaccine, mRNA-1215, in healthy adults(NCT05398796)[EB/OL].[2026-08-26]. https：//clinicaltrials. gov/study/NCT05398796.
[29]Peng Q, Dong Y, Jia M, et al. Cryo-EM structure of Nipah virus L-P polymerase complex[J]. Nat Commun, 2024, 15:10524. DOI:10. 1038/s41467-024-54994-5.
[30]Chen Z, Quirit Dudley J, Deniston C, et al. Cryo-EM structures of Nipah virus polymerases and highthroughput RdRp assay development enable anti-NiV drug discovery[J]. Nat Commun, 2025, 16:6655.DOI:10. 1038/s41467-025-61764-4.
[31]Isaacs A, Valenzuela Nieto G, Zhang X, et al. A nanobody-based therapeutic targeting Nipah virus limits viral escape[J]. Nat Struct Mol Biol, 2025, 32(10):1920-1931. DOI:10. 1038/s41594-025-01598-2.
[32]Sun YQ, Zhang YY, Liu MC, et al. Mapping the distribution of Nipah virus infections:a geospatial modelling analysis[J]. Lancet Planet Health, 2024, 8(7):e463-e475. DOI:10. 1016/S2542-5196(24)00119-0.
[33]Gurley ES, Plowright RK. A roadmap of primary pandemic prevention through spillover investigation[J].Emerg Infect Dis, 2025, 31(8):1501-1506. DOI:10. 3201/eid3108. 250442.
[34]McLean RK, Pedrera M, Thakur N, et al. Nipah virus vaccines evaluated in pigs as a‘One Health’ approach to protect public health[J]. NPJ Vaccines, 2025, 10:163. DOI:10. 1038/s41541-025-01212-y.
基本信息:
中图分类号:G353.1;R373
引用信息:
[1]蒋涛,郭建强,魏岚,等.1999-2025年全球尼帕病毒研究的知识基础、合作格局与主题演化——基于Web of Science的文献计量学可视化分析[J].病毒学报().
2026-09-04
2026-09-04
2026-09-04